Mariner LLC Buys 63,275 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Mariner LLC grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 198.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 95,215 shares of the biopharmaceutical company’s stock after acquiring an additional 63,275 shares during the period. Mariner LLC’s holdings in Regeneron Pharmaceuticals were worth $73,499,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the stock. Ellerson Group Inc. ADV raised its stake in shares of Regeneron Pharmaceuticals by 49.2% during the third quarter. Ellerson Group Inc. ADV now owns 8,102 shares of the biopharmaceutical company’s stock worth $4,556,000 after buying an additional 2,671 shares during the last quarter. Nordea Investment Management AB grew its holdings in Regeneron Pharmaceuticals by 118.1% during the fourth quarter. Nordea Investment Management AB now owns 137,321 shares of the biopharmaceutical company’s stock valued at $105,810,000 after purchasing an additional 74,350 shares during the period. TD Asset Management Inc grew its holdings in Regeneron Pharmaceuticals by 15.9% during the third quarter. TD Asset Management Inc now owns 374,264 shares of the biopharmaceutical company’s stock valued at $210,437,000 after purchasing an additional 51,407 shares during the period. Stevens Capital Management LP acquired a new position in Regeneron Pharmaceuticals during the third quarter valued at approximately $792,000. Finally, PNC Financial Services Group Inc. grew its holdings in Regeneron Pharmaceuticals by 17.7% during the third quarter. PNC Financial Services Group Inc. now owns 17,316 shares of the biopharmaceutical company’s stock valued at $9,736,000 after purchasing an additional 2,601 shares during the period. 83.31% of the stock is owned by institutional investors.

Analyst Ratings Changes

REGN has been the subject of a number of analyst reports. Leerink Partners restated a “market perform” rating and set a $641.00 price objective (down from $792.00) on shares of Regeneron Pharmaceuticals in a report on Monday, May 18th. Wells Fargo & Company decreased their price objective on shares of Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating for the company in a report on Monday, May 18th. Barclays decreased their price objective on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a report on Thursday, April 30th. Canaccord Genuity Group decreased their price objective on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a report on Tuesday, May 19th. Finally, TD Cowen boosted their price objective on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the company a “buy” rating in a report on Thursday, April 23rd. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $792.65.

Regeneron Pharmaceuticals Stock Up 0.5%

Regeneron Pharmaceuticals stock opened at $614.98 on Tuesday. The stock has a market capitalization of $65.02 billion, a PE ratio of 14.98, a price-to-earnings-growth ratio of 1.34 and a beta of 0.25. Regeneron Pharmaceuticals, Inc. has a twelve month low of $503.25 and a twelve month high of $821.11. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. The company has a 50 day moving average of $689.17 and a 200-day moving average of $736.78.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, beating the consensus estimate of $8.91 by $0.56. The company had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The business’s quarterly revenue was up 19.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $8.22 earnings per share. On average, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.44 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were issued a dividend of $0.94 per share. The ex-dividend date was Wednesday, May 20th. This represents a $3.76 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.16%.

Insider Buying and Selling

In related news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction on Friday, May 1st. The shares were sold at an average price of $705.24, for a total transaction of $70,524.00. Following the completion of the transaction, the director owned 17,503 shares in the company, valued at approximately $12,343,815.72. This represents a 0.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.